Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Next Previous
X
Search
Trial Profile

A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate-025
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 04 Jun 2024 Results analyzing the association between a germline IL7 SNP (rs16906115) and AEs in patients with mRCC treated with nivolumab (NIVO) or everolimus , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 07 Dec 2023 Results assessing whether PD-1 expression on intratumoral regulatory T cells is associated with lack of benefit from Anti-PD-1 therapy in metastatic clear cell renal cell carcinoma patients using multiparametric immunofluorescence in ccRCC tissues obtained from this study published in the Clinical Cancer Research
    • 01 Dec 2023 This trial has been completed in Spain (Date of the global end of the trial: 19-Jul-2021), according to the European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top